Kymera Therapeutics, Inc.
KYMR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,019,020 | $1,485,986 | $1,346,173 | $3,046,823 |
| - Cash | $120,256 | $109,966 | $68,395 | $47,976 |
| + Debt | $87,761 | $84,674 | $17,335 | $17,963 |
| Enterprise Value | $2,986,525 | $1,460,694 | $1,295,113 | $3,016,810 |
| Revenue | $47,072 | $78,592 | $46,826 | $72,832 |
| % Growth | -40.1% | 67.8% | -35.7% | – |
| Gross Profit | $47,072 | $78,592 | $46,826 | $72,832 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$216,236 | -$143,201 | -$151,655 | -$97,645 |
| % Margin | -459.4% | -182.2% | -323.9% | -134.1% |
| Net Income | -$223,858 | -$146,962 | -$154,808 | -$100,217 |
| % Margin | -475.6% | -187% | -330.6% | -137.6% |
| EPS Diluted | -2.98 | -2.52 | -2.87 | -2.09 |
| % Growth | -18.3% | 12.2% | -37.3% | – |
| Operating Cash Flow | -$194,501 | -$102,826 | -$153,085 | -$128,946 |
| Capital Expenditures | -$12,838 | -$34,480 | -$2,836 | -$1,597 |
| Free Cash Flow | -$207,339 | -$137,306 | -$155,921 | -$130,543 |